Vicki Moore, PhD

Contributing Writer https://www.cancertherapyadvisor.com

Vicki Moore, PhD, is a freelance medical writer for Hematology Advisor. Vicki received her PhD in biology from Arizona State University, where her research emphasized molecular biology, biochemistry, and metabolic engineering. She also has experience with predictive analytics and is intrigued by its applications to medicine. Vicki has been a medical writer, focusing on areas of hematology and oncology, among other specialties, since late 2017. You can find her on Linkedin at linkedin.com/in/vicki-moore-93950913

All articles by Vicki Moore, PhD

AACR 2023

Hereditary Cancer Syndromes Often Missed Under Current Screening Guidelines

Vicki Moore, PhD

April 19, 2023

Following genetic screening guidelines may cause clinicians to miss as many as 40% of patients with high-risk hereditary cancer syndromes, a study suggests.

AACR 2023

Pegargiminase Prolongs PFS, OS in Nonepithelioid Pleural Mesothelioma

Vicki Moore, PhD

April 18, 2023

Adding pegargiminase to standard frontline chemotherapy improves outcomes in patients with nonepithelioid pleural mesothelioma, a phase 2/3 study suggests.

AACR 2023

Pembrolizumab May Be Treatment of Choice for Unresectable Desmoplastic Melanoma

Vicki Moore, PhD

April 17, 2023

In a phase 2 trial, pembrolizumab produced an overall response rate of 89% in patients with unresectable desmoplastic melanoma.

AACR 2023

Frontline Pembrolizumab Improves OS in Advanced Biliary Tract Cancer

Vicki Moore, PhD

April 17, 2023

Adding pembrolizumab to frontline chemotherapy improves overall survival in patients with advanced biliary tract cancer, a phase 3 trial suggests.

Two positive pregnancy tests against a white background.

SGO 2023

Abortion Restrictions May Affect More than 20% of Pregnant Cancer Patients in the US

Vicki Moore, PhD

March 30, 2023

More than 20% of US patients diagnosed with cancer during pregnancy may be unable to terminate that pregnancy due to abortion laws in their state, a new study suggests.

SGO 2023

Time Spent on Health Care for Endometrial Cancer Negatively Affects Quality of Life

Vicki Moore, PhD

March 30, 2023

Patients with advanced or recurrent endometrial cancer spend about 15% of their time addressing health care needs, and this time burden can have a negative effect on their quality of life, a study suggests.

SGO 2023

Overall Survival Similar With or Without Niraparib Maintenance in Ovarian Cancer

Vicki Moore, PhD

March 29, 2023

Niraparib maintenance does not improve overall survival in patients with platinum-sensitive recurrent ovarian cancer, updated data suggest.

SGO 2023

Durvalumab, Tremelimumab, and Chemo Deemed Active in Advanced Ovarian Cancer

Vicki Moore, PhD

March 28, 2023

The combination of durvalumab, tremelimumab, and chemotherapy can produce durable responses in patients with newly diagnosed, advanced-stage epithelial ovarian cancer, a phase 2 trial suggests.

SGO 2023

Pembrolizumab Improves PFS in Advanced, Recurrent Endometrial Cancer

Vicki Moore, PhD

March 28, 2023

Adding pembrolizumab to chemotherapy improves progression-free survival in advanced or recurrent endometrial cancer, a phase 3 trial suggests.

SGO 2023

No Difference Between Chemoradiotherapy and Chemo Alone in Endometrial Cancer

Vicki Moore, PhD

March 27, 2023

Chemoradiotherapy does not improve overall survival, compared with chemotherapy alone, in patients with locally advanced endometrial cancer, a phase 3 trial suggests.

Next post in SGO 2023